Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 3/20 | 0.65 |
| ▸ | MME | P08473 | 3/20 | 0.65 |
| ▸ | ECE1 | P42892 | 1/20 | 0.53 |
| ▸ | CPA3 | P15088 | 1/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7608505 | 1.00 | CTRB1 (0.65) | CTRB1MMEECE1CPA3FOLH1 | |
| SCHEMBL8837460 | 0.83 | MME (0.73) | CTRB1MMEECE1CPA3FOLH1 | |
| SCHEMBL8837483 | 0.83 | CTRB1 (0.73) | CTRB1MMEECE1CPA3FOLH1 | |
| SCHEMBL7609959 | 0.82 | MME (0.57) | CTRB1MMEECE1 | |
| SCHEMBL7450894 | 0.80 | MME (0.52) | MME | |
| SCHEMBL8837489 | 0.80 | CTRB1 (0.73) | CTRB1MMEECE1CPA3FOLH1 | |
| SCHEMBL4325217 | 0.79 | MME (1.00) | CTRB1MMEECE1 | |
| SCHEMBL4325212 | 0.79 | MME (1.00) | CTRB1MMEECE1 | |
| SCHEMBL11493557 | 0.79 | CTRB1 (1.00) | CTRB1MMEECE1CPA3 | |
| SCHEMBL7304189 | 0.77 | CTRB1 (0.65) | CTRB1MMEECE1CPA3FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020161030-A1 | Sulpur derivatives containing a retroamide bond as inhibitors of endothelin-converting enzymes | HOECHST MARION ROUSSEL | 2002-10-31 | — | — | US | disclosed |
| US-6420341-B1 | TREATING VASOCONSTRICTOR AND HYPERTENSION EFFECTS IN WARM-BLOODED ANIMALS | AVENTIS PHARMA S.A. (FR) | 2002-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161030-A1 | Sulpur derivatives containing a retroamide bond as inhibitors of endothelin-converting enzymes | EDNRA, ECE1, EDNRB | CTRB1 451/4885MME 8/4885ECE1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.